Analyst consensus rating
ADC Therapeutics Analyst Rating: Buy
ADCT is rated Buy by 3 analysts with a $3.33 target. As of 2026-08-26.
Direct answer
ADC Therapeutics's consensus rating is Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.33.
Forecast evidence checked August 26, 2026.
Get free ADC Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.04
- Average price target
- $3.33
- High price target
- $5.00
- Low price target
- $2.00
- Low target gap
- +92.3%
- Target upside
- +220.5%
- High target gap
- +380.8%
- Target range width
- 288.5%
- Consensus rating
- Buy
- Analysts
- 3
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ADC Therapeutics?
ADC Therapeutics has a verified Buy consensus. The same dataset has an average price target of $3.33.
How far are ADC Therapeutics's low and high targets from the recorded price?
The low target implies +92.3%, while the high target implies +380.8%.
How many analysts are included in ADC Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is ADC Therapeutics's target upside or downside calculated?
The average target of $3.33 is divided by the recorded price of $1.04, then one is subtracted to produce +220.5%. This does not guarantee a future return.
When was ADC Therapeutics's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.